Tango Therapeutics (TNGX) Operating Margin (2020 - 2025)
Historic Operating Margin for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to 26.15%.
- Tango Therapeutics' Operating Margin rose 3094100.0% to 26.15% in Q3 2025 from the same period last year, while for Sep 2025 it was 165.91%, marking a year-over-year increase of 1560900.0%. This contributed to the annual value of 346.09% for FY2024, which is 335100.0% down from last year.
- Per Tango Therapeutics' latest filing, its Operating Margin stood at 26.15% for Q3 2025, which was up 3094100.0% from 1287.87% recorded in Q2 2025.
- In the past 5 years, Tango Therapeutics' Operating Margin registered a high of 26.15% during Q3 2025, and its lowest value of 1287.87% during Q2 2025.
- Over the past 5 years, Tango Therapeutics' median Operating Margin value was 432.41% (recorded in 2022), while the average stood at 440.58%.
- Within the past 5 years, the most significant YoY rise in Tango Therapeutics' Operating Margin was 3094100bps (2025), while the steepest drop was -11391800bps (2025).
- Tango Therapeutics' Operating Margin (Quarter) stood at 384.6% in 2021, then fell by -24bps to 476.79% in 2022, then crashed by -35bps to 644.69% in 2023, then tumbled by -54bps to 993.68% in 2024, then surged by 103bps to 26.15% in 2025.
- Its Operating Margin stands at 26.15% for Q3 2025, versus 1287.87% for Q2 2025 and 788.76% for Q1 2025.